Q-omics provides the consensus-scored PMP22 profile across patient tissues and cancer cell-line models. PMP22 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PMP22 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PMP22 RNA expression shows 22,807 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where PMP22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PMP22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PMP22 survival associations across molecular data types. PMP22 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PMP22 RNA expression–survival associations across cancer types. High PMP22 expression shows unfavorable associations in ACC, LGG and STAD, but favorable associations in UVM, UCS and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PMP22 RNA expression.
This table summarizes PMP22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PMP22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PMP22 shows lower tumor expression in BLCA, KICH, LUAD, THCA and LUSC and higher tumor expression in KIRC. The KIRC box plot shows higher PMP22 RNA expression in tumor versus normal tissue (log2 FC = +1.216, t-test p < 0.001).
This table shows molecular features associated with PMP22 in patient tissues and cancer cell lines. In patient samples, PMP22 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PMP22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
